SUMMARY INTRODUCTION. Accepted for publication 25 May 2005
|
|
- Camron Preston
- 5 years ago
- Views:
Transcription
1 Aliment Pharmacol Ther 2005; 22: doi: /j x Trends in the prevalence of peptic ulcer disease and Helicobacter pylori infection in family physician-referred uninvestigated dyspeptic patients in Hong Kong B.XIA*,H.H.X.XIA, C.W.MA*,K.W.WONG, F.M.Y.FUNG, C.K.HUI, C.K.CHAN, A. O. O. CHAN, K.C.LAI, M.F.YUEN &B.C.Y.WONG *Department of Internal Medicine, Research Center of Digestive Diseases of Zhongnan Hospital, Key Laboratory of Allergy and Immune-related Diseases, Wuhan University School of Medicine, China; Department of Medicine, The University of Hong Kong, Pokfulam, Hong Kong, China Accepted for publication 25 May 2005 SUMMARY Background: Peptic ulcer disease is mainly caused by Helicobacter pylori infection and the use of non-steroidal anti-inflammatory drugs. Aim: To investigate the trends in the prevalence of peptic ulcer disease, H. pylori infection and non-steroidal anti-inflammatory drug use in uninvestigated dyspeptic patients over recent years in Hong Kong. Methods: Data from consecutive patients with uninvestigated dyspeptic symptoms referred by family physicians for open access upper endoscopy during 1997 and 2003 were analysed in relation to peptic ulcer disease, H. pylori infection and non-steroidal anti-inflammatory drug use. Results: Among 2700 patients included, 405 (15%) had peptic ulcer disease and 14 (0.5%) had gastric cancer. There was a reduced trend from 1997 to 2003 in the prevalence of peptic ulcer disease (17, 20, 14, 16, 13, 14 and 14%, respectively, v 2 ¼ 5.80, P ¼ 0.016) (mainly because of decrease in duodenal ulcers), H. pylori infection (44, 50, 49, 44, 40, 40, 36 and 43%, respectively, v 2 ¼ 13.55, P < 0.001) and non-steroidal anti-inflammatory drug use (13, 5, 5, 6, 3, 4, 4 and 5% respectively, v 2 ¼ 13.61, P < 0.001). The prevalence of peptic ulcer disease, H. pylori infection and non-steroidal anti-inflammatory drug use between 2001 and 2003 were significantly lower than that between 1997 and 2000 (17% vs. 13%, OR ¼ 0.78, 95% CI: , P ¼ for peptic ulcer disease; 47% vs. 39%, OR ¼ 0.72, 95% CI: , P < for H. pylori infection; and 6% vs. 4%, OR ¼ 0.56, 95% CI: , P ¼ for non-steroidal anti-inflammatory drug use). H. pylori infection was associated with both duodenal ulcer (OR ¼ 15.87, 95% CI: , P < 0.001) and gastric ulcer (OR ¼ 3.12, 95% CI: , P < 0.001) whereas non-steroidal antiinflammatory drug use was only associated with gastric ulcer (OR ¼ 2.97, 95% CI: , P < 0.001). Conclusions: The prevalence of peptic ulcer disease, mainly duodenal ulcers, was reduced in association with a decreasing trend in the prevalence of H. pylori infection and non-steroidal anti-inflammatory drug use from 1997 to INTRODUCTION Correspondence to: Dr B. C. Y. Wong, Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Pokfulam, Hong Kong, China. bcywong@hku.hk Prevalence of peptic ulcer diseases (PUD) differs within countries. In China between 1977 and 1986, the average prevalence of duodenal ulcer in patients Ó 2005 Blackwell Publishing Ltd 243
2 244 B. XIA et al. undergoing upper endoscopy was 23% in the South and 9.7% in the North, with the average rate of duodenal ulcer almost doubling that of gastric ulcer. 1 It has been established that Helicobacter pylori infection is a major cause for PUD. 2 4 Approximately half of the world s populations are infected with H. pylori, according to the estimate by the World Health Organization. 3 Pooled data obtained in 1991 showed that the prevalence of H. pylori infection in patients with dyspepsia was reported to be about 60% in China. 5 Non-steroidal anti-inflammatory drugs (NSAIDs) are frequently used for various indications; 6 NSAID use increases with age, with 10 20% of the elderly having a current or recent NSAID prescription. 6 The use of NSAIDs is associated with various adverse events. Studies have shown that NSAID use is a major risk factor for non-h. pylori-associated PUD, especially gastric ulcer. 7, 8 Moreover, NSAIDs increase the risk of peptic ulcer complications by three to fivefold, and responsible for 15 35% of all peptic ulcer complications. 9, 10 Helicobacter pylori eradication therapy has become part of routine clinical practice for infected patients with PUD. 11, 12 Permanent cure of ulcers is achieved in most cases where H. pylori infection is successfully eradicated. 4 Following wide spread anti- H. pylori therapy in both primary practice and the hospital setting and particularly, the improvement of socio-economic and living conditions, the prevalence of H. pylori infection and PUD, especially duodenal ulcers, are decreasing in many countries. 4, 13, 14 The case is unknown in the Hong Kong Chinese population. Therefore, this study was carried out to investigate the trend in prevalence of PUD, H. pylori infection and frequency of NSAID use in uninvestigated dyspeptic patients referred by family physicians in Hong Kong Chinese. PATIENTS AND METHODS Source and collection of data Consecutive Chinese patients who were referred by family physicians to our open access endoscopy service, Medical Endoscopy Unit, Queen Mary Hospital from January 1997 to December 2003 with dyspeptic symptoms (defined as intermittent epigastric pain or discomfort) were analysed. Our open access endoscopy service was previously reported. 15 Briefly, family physicians in government general out-patient clinics were able to directly refer patients with uninvestigated dyspepsia to our open access endoscopy without prior consultation with a specialist. A special session was allocated to the open access service and over 90% of the cases were performed by a single endoscopist. 15 Data was collected using the computerized endoscopyreporting system established in 1993 in our unit. This system was specifically designed to collect the required information prospectively. Clinical information was recorded on a standard questionnaire before endoscopy, and entered into the reporting system, together with endoscopic findings after endoscopy. The clinical information included patient age and gender, major indication for upper endoscopy, duration of the symptoms, smoking and drinking history, concomitant diseases, use of aspirin and non-aspirin NSAIDs. Dosage and duration of NSAID use were also included. Endoscopic information included current endoscopic findings, lesion site, size and number if present. Helicobacter pylori status was determined using a rapid urease test on antral biopsy specimens, histological detection of Helicobacter-like organisms on biopsies taken from gastric antrum and body and/or 13 C-urea breath test. 16, 17 The rapid urease test as a single test for diagnosis of H. pylori infection has been validated in our centre with sensitivity, specificity, positive and negative predictive value of 99, 100, 100 and 99% respectively. 17 As some patients had more than one endoscopy performed during the period of study, the first endoscopy was used as an index endoscopy. However, when a patient had PUD or gastric cancer, the first endoscopy at which PUD or gastric cancer was diagnosed was used as an index endoscopy. Thus, each patient had one representative endoscopy. Patients with peptic ulcers (visible mucosal defect with diameter of 3 mm and depth 0.5 mm) and healed ulcers (ulcer scarring and/or duodenal deformity) in the stomach or duodenum were defined as having peptic ulcers. 18 The diagnosis of gastric cancer must be histologically confirmed. Patients who had used NSAIDs for at least 3 days at any dosage within 3 months prior to the index endoscopy were considered to be NSAID users. 7 All demographic, clinical and endoscopic data were retrieved. The cohort was divided into two groups based on the time period with roughly equal number in both groups, i.e. those between 1997 and 2000 (n ¼ 1369) and those between 2001 and 2003 (n ¼ 1331).
3 TRENDS IN PEPTIC ULCER DISEASE AND H. PYLORI 245 Statistical analysis The trend in the prevalence of PUD, gastric cancer, H. pylori infection, NSAID use, and the association among PUD, H. pylori infection and NSAID use in dyspeptic patients were analysed using the chi-squared test (with Yates correction if required), or the Fisher s exact test. Odds ratios (OR) and 95% confidence intervals (CI) were estimated where appropriate. Moreover, a multivariate logistic regression analysis including age and gender of patients, H. pylori infection and NSAID use was used to identify independent predictor (or risk) factor(s) for PUD. Difference in numeric data such as age between the groups was performed using the t-test or preformed using logistic regression analysis. All P-values calculated were two-tailed. The alpha level of significance was set at P < Statistical analyses were performed using SPSS11.5 software (SPSS, Inc., Chicago, IL, USA). RESULTS Overall trend in the prevalence of peptic ulcer, gastric cancer, Helicobacter pylori infection and non-steroidal anti-inflammatory drug use in dyspeptic patients During 1997 and 2003, data from 2700 patients referred by family physicians to our open access upper endoscopy were analysed. Among these patients, 405 (15.0%) were diagnosed as having PUD; 260 (9.6%) with duodenal ulcer, 129 (4.8%) with gastric ulcer and 16 (0.6%) with both duodenal and gastric ulcer. The overall prevalence of symptomatic PUD, gastric cancer, H. pylori infection and NSAIDs use in this population was 15.0, 0.5, 42.8 and 5.1%, respectively. There was a reduced trend in the prevalence of PUD (P ¼ 0.016), H. pylori infection (P < 0.001) and NSAIDs use (P < 0.001) (Table 1 and Figure 1). Comparison of the demographic, clinical and endoscopic data of dyspeptic patients between and The mean age of the patients was significantly younger between 2001 and 2003 than that between 1997 and 2000 (46.0 ± 15.6 vs ± 16.4 years old, P ¼ 0.011). However, there was no change in the gender distribution during the two periods of time. The prevalence of PUD between 2001 and 2003 were significantly lower than that between 1997 and 2000 (16.6% vs. 13.4%, OR ¼ 0.78, 95% CI: , P ¼ 0.020). Table 1. Trend in the prevalence of peptic ulcer disease, gastric cancer, Helicobacter pylori infection and non-steroidal anti-inflammatory drug (NSAID) use in dyspeptic patients referred by general practitioners between 1997 and 2003 v 2 for trend P value Total (n ¼ 2700) 2003 (n ¼ 329) 2002 (n ¼ 534) 2001 (n ¼ 468) 2000 (n ¼ 433) 1999 (n ¼ 365) 1998 (n ¼ 365) 1997 (n ¼ 206) Peptic ulcer disease 35 (17.0) 72 (19.7) 50 (13.7) 70 (16.2) 61 (13.0) 72 (13.5) 45 (13.7) 405 (15.0) Duodenal ulcer* 24 (11.7) 51 (14.0) 37 (10.1) 46 (10.6) 45 (9.6) 47 (8.8) 26 (7.9) 276 (10.2) Gastric ulcer* 12 (5.8) 23 (6.3) 13 (3.6) 29 (6.7) 19 (4.1) 30 (5.6) 19 (5.8) 145 (5.3) Gastric cancer 1 (0.5) 1 (0.3) 4 (1.1) 2 (0.5) 1 (0.2) 2 (0.4) 3 (0.9) 14 (0.5) Helicobacter pylori 42/95 (44.2) 136/275 (49.5) 128/161 (49.0) 148/338 (43.8) 158/396 (39.9) 134/334 (40.2) 98/273 (35.9) 844/1971 (42.8) < infection NSAID use 26/194 (13.4) 16/344 (4.7) 18/344 (5.2) 21/385 (5.5) 14/438 (3.2) 17/441 (3.9) 13/314 (4.1) 125/2460 (5.1) <0.001 The numbers in parentheses are percentages. * 16 cases had both gastric and duodenal ulcer. Data were not available for some cases.
4 246 B. XIA et al. 50% 45% 40% Prevalence 35% 30% 25% 20% 15% 10% 5% 0% Year H. pylori infection Peptic ulcer disease Duodenal ulcer Gastric ulcer NSAID use Gastric cancer Figure 1. Trend in the prevalence of peptic ulcer disease, gastric cancer, Helicobacter pylori infection and non-steroidal antiinflammatory drugs use in dyspeptic patients between 1997 and While the prevalence of duodenal ulcer was significantly reduced, the prevalence of gastric ulcer remained stable (Table 2). The prevalenceof H. pylori infection and NSAID use between 2001 and 2003 was significantly lower than that between 1997 and 2000 (46.9% vs. 38.9%, OR ¼ 0.73, 95% CI: , P < for H. pylori infection; 6.4% vs. 3.7%, OR ¼ 0.56, 95% CI: , P ¼ for NSAID use) (Table 2). No change in the prevalence of gastric cancer was observed (Table 2). Association of peptic ulcer disease with gender, and age of patients, Helicobacter pylori infection and non-steroidal anti-inflammatory drug use The prevalence of PUD was significantly higher in men than in women (54.1% vs. 35.5%, OR ¼ 2.09, 95% CI: , P < 0.001). Patients with PUD were significantly older than those without PUD (51.2 ± 14.9 vs ± 16.4 years old, P ¼ 0.01). Helicobacter pylori infection was significantly associated with PUD (OR ¼ 9.46, 95% CI: , P < 0.001) including both duodenal ulcer (OR ¼ 15.87, 95% CI: , P < 0.001) and gastric ulcer (OR ¼ 3.12, 95% CI: , P < 0.001). Although NSAID use was not associated with overall PUD (OR ¼ 1.35, 95% CI: , P ¼ 0.201) and duodenal ulcer, it was significantly associated with gastric ulcer (OR ¼ 2.97, 95% CI: , P < 0.001) (Table 3). Moreover, patients with H. pylori infection and/or NSAID use were more likely to have PUD (OR ¼ 9.541, 95% CI: , P < 0.001), including both duodenal ulcer (OR ¼ 16.86, 95% CI: , P < 0.001) and gastric ulcer (OR ¼ 3.34, 95% CI: , P < 0.001). Table 2. Demographic and clinical data of dyspeptic patients between 1997 and 2000 and between 2001 and (n ¼ 1369) (n ¼ 1331) Total (n ¼ 2700) Gender Male 509 (37.2%) 512 (38.5%) 1021 (37.8%) Female 860 (62.8%) 819 (61.5%) 1679 (62.2%) Age (year) Mean age (mean ± SD) 51.3 ± ± ± 16.2 Range NSAID users* 81/1267 (6.4%) 44/1193 (3.7%)à 125/2460 (5.1%) Helicobacter pylori positive cases* 454/969 (46.9%) 390/1002 (38.9%) 844/1971 (42.8%) Peptic ulcer disease 227 (16.6%) 178 (13.4%) 405 (15.0%) Duodenal ulcer 150 (11.0%) 110 (8.3%) 260 (9.6%) Gastric ulcer 69 (5.0%) 60 (4.5%) 129 (4.8%) Duodenal/gastric ulcer 8 (0.6%) 8 (0.6%) 16 (0.6%) Gastric cancer 8 (0.6%) 6 (0.5%) 14 (0.5%) Other gastrointestinal diseases 12 (0.9%) 4 (0.3%) 16 (0.6%) * Data were not available for some cases. Compared with , P < à Compared with , P < Compared with , P <
5 TRENDS IN PEPTIC ULCER DISEASE AND H. PYLORI 247 Table 3. Association of peptic ulcer disease (PUD), including duodenal ulcer (DU) and gastric ulcer (GU), with Helicobacter pylori infection and non-steroidal anti-inflammatory drug (NSAID) use in dyspeptic patients between 1997 and Total PUD DU* GU* Total PUD DU* GU* Total PUD DU* GU* Helicobacter pylori status Positive (41.0%) 142 (31.3%) 51 (11.2%) (34.9%) 101 (25.9%) 42 (10.8%) (38.2%) 243 (28.8%) 93 (11.0%) Negative (6.8%) 14 (2.7%) 22 (4.3%) (5.6%) 14 (2.3%) 21 (3.4%) (6.1%) 28 (2.5%) 43 (3.8%) NSAID use Yes (21.0%) 10 (12.3%) 9 (11.1%)à 44 7 (15.9%) 0 (0%) 7 (15.9%) (19.2%) 10 (8%) 16 (12.8%) No (16.9%) 146 (12.3%) 60 (5.1%) (12.9%) 103 (9.0%) 50 (4.4%) (14.9%) 249 (10.7%) 110 (4.7%) Helicobacter pylori infection and/or NSAID use Yes (37.4%) 145 (28.2%) 55 (10.7%) (33.1%) 101 (24.0%) 45 (10.7%) (35.4%) 246 (26.3%) 100 (10.7%) No (6.3%) 11 (2.4%) 18 (3.9%) (4.7%) 10 (1.8%) 17 (3.1%) (5.4%) 21 (2.1%) 35 (3.5%) * Some cases had both gastric and duodenal ulcer. Compared with H. pylori negative cases, non-nsaid users or H. pylori negative non-nsaid users, where appropriate, P < 0.001; à Compared with non-nsaid users, P ¼ Using the multivariate logistic regression analysis, male gender (OR ¼ 2.09, 95% CI: , P < 0.001), increasing age (OR ¼ 0.99, 95% CI: , P ¼ 0.026) of the patients and positive H. pylori infection (OR ¼ 5.41, 95% CI: , P < 0.001), but not NSAID use, were identified as independent risk factors for PUD. Non-steroidal anti-inflammatory drug users were significantly older than non-nsaid users (59.8 ± 15.9 vs ± 15.9 years old, P < 0.001), although NSAID use was not associated with gender of patients. There was no significant difference in the prevalence of H. pylori infection between NSAID users and non- NSAID users (38.9% vs. 43.0%, OR ¼ 0.84, 95% CI: , P ¼ 0.444). However, in patients with PUD, the prevalence of H. pylori infection in NSAID users was significantly lower than that in non-nsaid users (65.2% vs. 84.0%, OR ¼ 0.36, 95% CI: , P ¼ 0.021). DISCUSSION In the present study, the prevalence of duodenal ulcer, H. pylori infection and NSAID use all decreased from 1997 to 2003 in uninvestigated dyspeptic patients in Hong Kong, but that of gastric ulcer and gastric cancer remained unchanged. This phenomenon after widespread application for H. pylori eradication therapy was also observed in other studies. 19 Our study confirms that the decreased trend in prevalence of PUD, mainly duodenal ulcer, is associated with a decrease in H. pylori infection. We did not find any association between NSAID use and overall prevalence of PUD, after adjusting for confounding factors including age, gender of the patients and H. pylori infection. However, our further analysis showed that NSAID use was associated with gastric ulcer, but not with duodenal ulcer. This observation is in agreement with a previous study demonstrating that NSAIDs are associated with the development of gastric ulcers, independent of H. pylori infection. 8 Many previous studies have shown that H. pylori infection is inversely associated with NSAID use In a recent large cross-sectional endoscopic trial, the prevalence of H. pylori infection was significantly lower in NSAID users with gastric ulcers than in those without ulcers. 20 Indeed, previous studies have also shown that between 30 and 75% of H. pylori negative ulcer patients are NSAID users, whereas <30% of H. pylori positive ulcer patients are NSAID users
6 248 B. XIA et al. The reason for such inverse association is unknown, but it is likely to be explained by the observations that NSAIDs have bacteriostatic or inhibitory activity against H. pylori, 24, 25 and thus occasionally eliminate the organism with or without use of one or more antimicrobial agents. In the present study, we also found in patients with PUD, the prevalence of H. pylori infection in NSAID users was significantly lower than in non-nsaid users, which is consistent with the crosssectional endoscopic trial. It has been reported in a meta-analysis that H. pylori infection and NSAIDs independently and significantly increase the relative risk of PUD. 26 Moreover, H. pylori infection significantly increases the risk of ulcer in NSAID users compared with non-nsaid users. Eradication of H. pylori has been recommended for the management of PUD. 27 However, there are controversies regarding eradication therapy in patients on longterm NSAID treatment for the prevention of PUD and the associated complications. Sung 28 showed that eradication of H. pylori infection reduced the risk of ulcer and the complications in patients requiring NSAIDs and aspirin. Lanas 29 showed that proton pump inhibitors or H. pylori eradication seemed the best option to reduce the incidence of upper gastrointestinal bleeding in patients taking low-dose aspirin. However, Lai et al. 30, 31 reported that the eradication of H. pylori infection in patients receiving long-term NSAID treatment was not sufficient to prevent ulcer development, and proton pump inhibitors are required. In the present study, there was no reduction in the prevalence of gastric cancer and gastric ulcer over 7 years, despite an active H. pylori eradication in Hong Kong. In a high-risk region of China, eradication of H. pylori infection in individuals without precancerous lesions significantly decreases the incidence of gastric cancer during 7.5-year follow-up period. 32 However, the sample size of the present study was not adequate (n ¼ 2700), and the follow-up period (7 years) was also insufficient for the determination of the trend in the incidence of gastric cancer after some eradication of H. pylori infection. Also for these reasons, it is not feasible to assess the association between gastric cancer and other factors such as H. pylori infection and NSAID use in the present study. In conclusion, the prevalence of PUD, mainly duodenal ulcers, was reduced, in association with a decreasing trend in the prevalence of H. pylori infection and NSAID use from 1997 to ACKNOWLEDGEMENTS Prof. B. Xia was a visiting professor, financially supported by the Sun Yat Sen Foundation Fund for Academic Exchanges with China, Faculty of Medicine, The University of Hong Kong, for this study. We thank nurse specialist M. Chong, and endoscopy nurses V.S.Y. Tang, D.K.K. Chang, and W.P. Yung, and technician Mr Hess Cheung for assistance; and Mr James Ma of Queen Mary Hospital, Hong Kong, for the computer endoscopy reporting system. REFERENCES 1 Wong BCY, Ching CK, Lam SK, et al. Differential north to south gastric cancer duodenal ulcer gradient in China. J Gastroenterol Hepatol 1998; 13: Warren JR, Marshall B. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet 1983; 1: International Agency for Research on Cancer, World Health Organization. Infection with Helicobacter pylori, schistosomes, liver flukes and Helicobacter pylori, IARC, Lyon, 1994 Monogr. Eval Carcinog Risks Hum 1994; 60: Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease. Helicobacter pylori in peptic ulcer disease. JAMA 1994; 272: Li YY, Hu PJ, Du GG, Hazell SL. The prevalence of Helicobacter pylori infection in the Peoples Republic of China. Am J Gastroenterol 1991; 86: Griffin MR, Piper JM, Daugherty JR, Snowden M, Ray WA. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med 1991; 114: Xia HHX, Kalantar JS, Mitchell HM, Talley NJ. Can Helicobacter pylori serology still be a surrogate marker to identify peptic ulcer disease in dyspepsia? Aliment Pharmacol Ther 2000; 14: Laine L, Marin-Sorensen M, Weinstein WM. Nonsteroidal antiinflammatory drug-associated gastric ulcers do not require Helicobacter pylori for their development. Am J Gastroenterol 1992; 87: Henry D, Lim LLY, Garc a Rodr guez LA, et al. Variability in risk of gastrointestinal complications with individual nonsteroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ 1996; 312: Luis AGR, Sonia HD. Risk of uncomplicated peptic ulcer among users of aspirin and nonaspirin nonsteroidal antiinflammatory drugs. Am J Epidemiol 2004; 159: Xia HHX, Wong BCY, Talley NJ, Lam SK. Helicobacter pylori infection current treatment practice. Expert Opin Pharmacother 2001; 2: Xia HHX, Wong BCY, Talley NJ, Lam SK. Alternative and rescue treatment regimens for Helicobacter pylori eradication. Expert Opin Pharmacother 2002; 3:
7 TRENDS IN PEPTIC ULCER DISEASE AND H. PYLORI Sonnenberg A. Temporal trends and geographical variations of peptic ulcer disease. Aliment Pharmacol Ther 1995; 9(Suppl. 2): Xia HHX, Phung N, Altiparmak E, Berry A, Matheson M, Talley NJ. Reduction of peptic ulcer disease and Helicobacter pylori infection but increase of reflux esophagitis in western Sydney between 1990 and Dig Dis Sci 2001; 46: Wong BCY, Wong KW, Chan CK, et al. Evaluation of a new referral system for the management of dyspepsia in Hong Kong: role of open access upper endoscopy. J Gastroenterol Hepatol 2000; 15: Wong BCY, Xiao SD, Hu FL, et al. Comparison of lansoprazolebased triple therapy for treatment of Helicobacter pylorirelated duodenal ulcer: an Asian multicentre double-blind randomized placebo controlled study. Aliment Pharmacol Ther 2000; 14: Wong BCY, Wong WM, Wang WH, et al. An evaluation of invasive and non-invasive tests for the diagnosis of Helicobacter pylori infection in Chinese. Aliment Pharmacol Ther 2001; 15: Xia HHX, Wong BCY, Wong KW, et al. Clinical and endoscopic characteristics of non-helicobacter pylori, non- NSAID duodenal ulcers: a long-term prospective study. Aliment Pharmacol Ther 2001; 15: Kearney DJ, Liu CF, Crump C, Brousal A. The effect of a Helicobacter pylori treatment strategy on health care expenditures in patients with peptic ulcer disease and dyspepsia. Am J Gastroenterol 2003; 98: Matsukawa Y, Aoki M, Nishinarita S, et al. Prevalence of Helicobacter pylori in NSAID users with gastric ulcer. Rheumatology (Oxford) 2003; 42: Nensey YM, Schubert TT, Bologna SD, Ma CK. Helicobacter pylori-negative duodenal ulcer. Am J Med 1991; 91: Borody TJ, George LL, Brandl S, et al. Helicobacter pylorinegative duodenal ulcer. Am J Gastroenterol 1991; 86: Kemppainen H, Raiha I, Kujari H, Sourander L. Characteristics of Helicobacter pylori-negative and -positive peptic ulcer disease. Age Ageing 1998; 27: Wang WH, Wong WM, Dailidiene D, et al. Aspirin inhibits the growth of Helicobacter pylori and enhances its susceptibility to antimicrobial agents. Gut 2003; 52: Gu Q, Xia HHX, Wang WH, et al. Effect of cyclo-oxygenase inhibitors on Helicobacter pylori susceptibility to metronidazole and clarithromycin. Aliment Pharmacol Ther 2004; 20: Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in pepticulcer disease: a meta-analysis. Lancet 2002; 8: Kuipers EJ, Malfertheiner P. Helicobacter pylori and nonmalignant diseases. Helicobacter 2004; 9(Suppl. 1): Sung JJY. Should we eradicate Helicobacter pylori in nonsteroidal anti-inflammatory drug users? Aliment Pharmacol Ther 2004; 20(Suppl. 2): Lanas A. Prevention of aspirin-induced gastroduodenal damage: H. pylori infection eradication versus proton pump inhibitors or both. Dig Liver Dis 2004; 36: Lai KC, Lau CS, Ip WY, et al. Effect of treatment of Helicobacter pylori on the prevention of gastroduodenal ulcers in patients receiving long-term NSAIDs: a double-blind, placebo-controlled trial. Aliment Pharmacol Ther 2003; 17: Lai KC, Lam SK, Chu KM, et al. Lansoprazole reduces ulcer relapse after eradication of Helicobacter pylori in nonsteroidal anti-inflammatory drug users a randomized trial. Aliment Pharmacol Ther 2003; 18: Wong BC, Lam SK, Wong WM, et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA 2004; 291:
Dr. LEUNG Lok Hang, Will
Direct access endoscopy booking by family physicians: evaluating a new service model and clinical predictors of positive endoscopy findings at primary care setting Dr. LEUNG Lok Hang, Will Department of
More informationPREVENTING ASPIRIN-RELATED ULCER COMPLICATIONS
PREVENTING ASPIRIN-RELATED ULCER COMPLICATIONS LANSOPRAZOLE FOR THE PREVENTION OF RECURRENCES OF ULCER COMPLICATIONS FROM LONG-TERM LOW-DOSE ASPIRIN USE KAM CHUEN LAI, M.R.C.P., SHIU KUM LAM, M.D., KENT
More informationManagement of dyspepsia and of Helicobacter pylori infection
Management of dyspepsia and of Helicobacter pylori infection The University of Nottingham John Atherton Wolfson Digestive Diseases Centre University of Nottingham, UK Community management of dyspepsia
More informationWhat is the status of Sequential Therapy Versus Standard Triple- Drug Therapy in peptic ulcer disease in eradicating H pylori?
What is the status of Sequential Therapy Versus Standard Triple- Drug Therapy in peptic ulcer disease in eradicating H pylori? Sequential Therapy Versus Standard Triple- Drug Therapy for Helicobacter pylori
More informationLow-dose rabeprazole, amoxicillin and metronidazole triple therapy for the treatment of Helicobacter pylori infection in Chinese patients
Blackwell Science, LtdOxford, UKJGHJournal of Gastroenterology and Hepatology0815-93192005 Blackwell Publishing Asia Pty Ltd206935940Original ArticleLow-dose rabeprazole-based triple therapywm Wong et
More informationHelicobacter Pylori Testing HELICOBACTER PYLORI TESTING HS-131. Policy Number: HS-131. Original Effective Date: 9/17/2009
Easy Choice Health Plan, Inc. Harmony Health Plan of Illinois, Inc. Missouri Care, Inc. Ohana Health Plan, a plan offered by WellCare Health Insurance of Arizona, Inc. WellCare Health Insurance of Illinois,
More informationThree-day lansoprazole quadruple therapy for Helicobacter pylori-positive duodenal ulcers: a randomized controlled study
Aliment Pharmacol Ther 2001; 15: 843±849. Three-day lansoprazole quadruple therapy for Helicobacter pylori-positive duodenal ulcers: a randomized controlled study B. C. Y. WONG*, W. H. WANG*, W.M.WONG*,G.K.K.LAU*,F.M.Y.FUNG*,N.N.S.KUNGà,
More informationPDF hosted at the Radboud Repository of the Radboud University Nijmegen
PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/48400
More informationCOMPARISON OF ONCE-A-DAY VERSUS TWICE-A-DAY CLARITHROMYCIN IN TRIPLE THERAPY FOR HELICOBACTER PYLORI ERADICATION
Phil J Gastroenterol 2006; 2: 25-29 COMPARISON OF ONCE-A-DAY VERSUS TWICE-A-DAY CLARITHROMYCIN IN TRIPLE THERAPY FOR HELICOBACTER PYLORI ERADICATION Marianne P Collado, Ma Fatima P Calida, Peter P Sy,
More informationBleeds in Cardiovascular Disease
Preventing Gastrointestinal Bleeds in Cardiovascular Disease Patients t on Aspirin i Joel C. Marrs, Pharm.D., BCPS Clinical Assistant Professor OSU/OHSU College of Pharmacy Pharmacy Practice IX (PHAR 766)
More informationAssessment of symptomatic response as predictor of Helicobacter pylori status following eradication therapy in patients with ulcer
618 University Department of Medicine and Therapeutics, Western Infirmary, Glasgow G11 6NT, UK K E L McColl A El-Nujumi L S Murray E M El-Omar A Dickson A W Kelman T E Hilditch Correspondence to: Professor
More informationTreatment of Helicobacter pylori Infection
Treatment of Helicobacter pylori Infection Epidemiology of H. pylori infection (North America) Which are the high risk groups? Epidemiology of H. pylori infection (North America) Which are the high risk
More informationMaastricht Ⅴ /Florence
2016 21 10 577 Maastricht Ⅴ /Florence 200001 2015 10 8 9 Maastricht V 1 / 2 3 4 / 5 Maastricht Ⅴ Interpretation of Management of Helicobacter pylori Infection the Maastricht Ⅴ / Florence Consensus Report
More informationHelicobacter 2008;13:1-6. Am J Gastroent 2007;102: Am J of Med 2004;117:31-35.
An Update on Helicobacter pylori and Its Treatment Trenika Mitchell, PharmD, BCPS Clinical Assistant Professor University of Kentucky College of Pharmacy October 18, 2008 Objectives Review the epidemiology
More informationReview Article. NSAID Gastropathy: An Update on Prevention. Introduction. Risk Factors. Kam-Chuen Lai
Review Article NSAID Gastropathy: An Update on Prevention Kam-Chuen Lai Abstract: Keywords: Adverse reactions to non-steroidal anti-inflammatory drugs (NSAIDs) are common. Upper gastrointestinal complications
More informationHelicobacter pylori: Diagnosis, treatment and risks of untreated infection
Helicobacter pylori: Diagnosis, treatment and risks of untreated infection Klaus Mönkemüller Department of Gastroenterology, Hepatology und Infectius Diseases Otto-von-Guericke University, Magdeburg bb
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: helicobacter_pylori_testing 01/01/2019 N/A 01/01/2020 01/01/2019 Policy Effective April 1, 2019 Description
More informationNg, W; Wong, WM; Chen, WH; Tse, HF; Lee, PY; Lai, KC; Li, SW; Ng, M; Lam, KF; Cheng, X; Lau, CP
Title Author(s) Incidence and predictors of upper gastrointestinal bleeding in patients receiving low-dose aspirin for secondary prevention of cardiovascular events in patients with coronary artery disease
More informationComparison of the Accuracy of Two Commercial Rapid Urase Tests, CLOtest and Pronto Dry, in Detecting Helicobacter pylori Infection ABSTRACT
Original Article Rojborwonwitaya J, Vijitjunyakul N THAI J GASTROENTEROL 2005 Vol. 6 No. 2 May - Aug. 2005 55 Comparison of the Accuracy of Two Commercial Rapid Urase Tests, CLOtest and Pronto Dry, in
More informationSELECTED ABSTRACTS. Figure. Risk Stratification Matrix A CLINICIAN S GUIDE TO THE SELECTION OF NSAID THERAPY
SELECTED ABSTRACTS A CLINICIAN S GUIDE TO THE SELECTION OF NSAID THERAPY The authors of this article present a 4-quadrant matrix based on 2 key clinical parameters: risk for adverse gastrointestinal (GI)
More informationHelicobacter pylori infection: several studies on epidemiology, eradication and gastric epithelial cell turnover Liu, W.
UvA-DARE (Digital Academic Repository) Helicobacter pylori infection: several studies on epidemiology, eradication and gastric epithelial cell turnover Liu, W. Link to publication Citation for published
More informationHigh Recurrence Rate of Idiopathic Peptic Ulcers in Long-Term Follow-up
Gut and Liver, Vol. 7, No. 2, March 2013, pp. 175-181 ORiginal Article High Recurrence Rate of Idiopathic Peptic Ulcers in Long-Term Follow-up Hyuk Yoon, Sang Gyun Kim, Hyun Chae Jung, and In Sung Song
More informationMagaji et al., Afr. J. Infect. Dis. 2(2): THE ROLE OF AN AGGRESSIVE FACTOR IN PEPTIC ULCER DISEASE (PUD)
Magaji et al., Afr. J. Infect. Dis. 2(2): 80-84 80 Review Paper ISSN: 2006-0165 2008 THE ROLE OF AN AGGRESSIVE FACTOR IN PEPTIC ULCER DISEASE (PUD) Magaji, R.A. 1,b *, Tanko, Y. 2 and Magaji, G.M. 3 Afr.
More informationProton Pump Inhibitors Drug Class Prior Authorization Protocol
Proton Pump Inhibitors Drug Class Prior Authorization Protocol Line of Business: Medi-Cal P&T Approval Date: November 15, 2017 Effective Date: January 1, 2018 This policy has been developed through review
More informationReview article: management of peptic ulcer bleeding the roles of proton pump inhibitors and Helicobacter pylori eradication
Aliment Pharmacol Ther 2004; 19 (Suppl. 1): 66 70. Review article: management of peptic ulcer bleeding the roles of proton pump inhibitors and Helicobacter pylori eradication G. HOLTMANN* & C. W. HOWDEN
More informationSetting The setting was secondary care. The economic study was carried out in Hong Kong, China.
Cost-effectiveness of Helicobacter pylori "test and treat" for patients with typical reflux symptoms in a population with a high prevalence of H. pylori infection: a Markov model analysis You J H, Wong
More informationCHAPTER 18. PEPTIC ULCER DISEASE, SELF-ASSESSMENT QUESTIONS. 1. Which of the following is not a common cause of peptic ulcer disease (PUD)?
CHAPTER 18. PEPTIC ULCER DISEASE, SELF-ASSESSMENT QUESTIONS 1. Which of the following is not a common cause of peptic ulcer disease (PUD)? A. Chronic alcohol ingestion B. Nonsteroidal antiinflammatory
More informationPrevalence of gastroduodenal lesions in chronic nonsteroidal anti-inflammatory drug users presenting with dyspepsia at the Kenyatta National Hospital
Research Article Department of Clinical Medicine and Therapeutics, University of Nairobi, Kenya Corresponding author: Dr. G O Oyoo. Email: geomondi@hotmail. com Prevalence of gastroduodenal lesions in
More informationPeptic Ulcer Disease Update
Peptic Ulcer Disease Update Col Pat Storms RAM 2005 Disclosure Information 84th Annual AsMA Scientific Meeting Col Patrick Storms I have no financial relationships to disclose. I will discuss the following
More informationHigh use of maintenance therapy after triple therapy regimes in Ireland
High use of maintenance therapy after triple therapy regimes in Ireland K Bennett, H O Connor, M Barry, C O Morain, J Feely Department of Pharmacology & Therapeutics Department of Gastroenterology Trinity
More informationACG Clinical Guideline: Treatment of Helicobacter pylori Infection
ACG Clinical Guideline: Treatment of Helicobacter pylori Infection William D. Chey, MD, FACG 1, Grigorios I. Leontiadis, MD, PhD 2, Colin W. Howden, MD, FACG 3 and Steven F. Moss, MD, FACG 4 1 Division
More informationHelicobacter pylori Eradication Therapy Success Regarding Different Treatment Period Based on Clarithromycin or Metronidazole Triple-Therapy Regimens
Helicobacter ISSN 1523-5378 Filipec Blackwell Oxford, HEL 1083-4389 1523-5378 Journal XXX Original H. 2008 pylori Kanizaj compilation The UK Eradication Publishing Article Authors et al. Ltd 2008 Therapy
More informationinstrument. When 13C-UBT positive value is greater than or equal to / - 0.4, the the subject can be 1. Data and methods details are as follows:
Application of 13 C-urea breath test in screening helicobacter pylori infection during health examination in Chengdu, Sichuan YANG Yan-hua. LIU Yu-ping. CHENG You-fu, SHUAI Ping. LU Qiao. ZHENG Xiao-xia,
More informationMitigating GI Risks Associated with the Use of NSAIDs
bs_bs_banner Pain Medicine 2013; 14: S18 S22 Wiley Periodicals, Inc. Mitigating GI Risks Associated with the Use of NSAIDs Mahnaz Momeni, MD,* and James D. Katz, MD Departments of *Rheumatology, Medicine,
More informationHelicobacter pylori Improved Detection of Helicobacter pylori
DOI:http://dx.doi.org/10.7314/APJCP.2016.17.4.2099 RESEARCH ARTICLE Improved Detection of Helicobacter pylori Infection and Premalignant Gastric Mucosa Using Conventional White Light Source Gastroscopy
More informationPeptic Ulcer Bleeding Risk. The Role of Helicobacter Pylori Infection in NSAID/Low-Dose Aspirin Users
684 ORIGINAL CONTRIBUTIONS nature publishing group see related editorial on page x Peptic Ulcer Bleeding Risk. The Role of Helicobacter Pylori Infection in NSAID/Low-Dose Aspirin Users C. Sostres, MD 1,
More informationUrea Breath Test for Diagnosis of Helicobactor pylori. Original Policy Date 12:2013
MP 2.04.04 Urea Breath Test for Diagnosis of Helicobactor pylori Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date 12:2013 Return to Medical Policy Index
More informationManagement of Dyspepsia
MPharm Programme Management of Dyspepsia Slide 1 of 28 Learning Objectives Understand the principles and wider implications underpinning evidence based therapeutics in the key clinical specialities Objectively
More informationEarly Helicobacter pylori Eradication Decreases Risk of Gastric Cancer in Patients With Peptic Ulcer Disease
GASTROENTEROLOGY 2009;137:1641 1648 Early Helicobacter pylori Eradication Decreases Risk of Gastric Cancer in Patients With Peptic Ulcer Disease CHUN YING WU,*,, KEN N. KUO, MING SHIANG WU, YI JU CHEN,,#
More informationKEYWORDS Dyspepsia, Acid Peptic Disease, Helicobacter Pylori, Urease, Giemsa, Peptic Ulcer, Non-Ulcer Dyspepsia.
INCIDENCE OF HELICOBACTER PYLORI WITH ACID PEPTIC DISEASE AND MALIGNANT CONDITIONS OF UPPER GASTROINTESTINAL TRACT IN A TERTIARY CENTRE - A PROSPECTIVE STUDY Karunamoorthy Rajachidambaram 1, Dinkaran Kaarthesan
More informationHelicobacter pylori. Objectives. Upper Gastrointestinal Bleeding Peptic Ulcer Disease
Upper Gastrointestinal Bleeding Peptic Ulcer Disease Pharmacotherapy Issues in Acute Management and Secondary Prevention Peter J. Zed, B.Sc., B.Sc.(Pharm), Pharm.D. Pharmacotherapeutic Specialist - Emergency
More informationThe significance of Helicobacter pylori in the approach of dyspepsia in primary care Arents, Nicolaas Lodevikus Augustinus
University of Groningen The significance of Helicobacter pylori in the approach of dyspepsia in primary care Arents, Nicolaas Lodevikus Augustinus IMPORTANT NOTE: You are advised to consult the publisher's
More informationAmerican College of Gastroenterology Guideline on the Management of Helicobacter pylori Infection
American Journal of Gastroenterology ISSN 0002-9270 C 2007 by Am. Coll. of Gastroenterology doi: 10.1111/j.1572-0241.2007.01393.x Published by Blackwell Publishing American College of Gastroenterology
More informationAn evaluation of whole blood testing for Helicobacter pylori in general practice
Aliment Pharmacol Ther 1998; 12: 641±645. An evaluation of whole blood testing for Helicobacter pylori in general practice N. J. TALLEY, J. R. LAMBERT*, S. HOWELL, H. H.-X. XIA, S. K. LIN* & L. AGREUS
More informationUse of NSAIDs and infection with Helicobacter pylori what does the rheumatologist need to know?
Rheumatology 2008;47:1342 1347 Advance Access publication 13 May 2008 doi:10.1093/rheumatology/ken123 Use of NSAIDs and infection with Helicobacter pylori what does the rheumatologist need to know? U.
More informationPEPTIC ULCER DISEASE JOHN R SALTZMAN, MD. Director of Endoscopy Brigham and Women s Hospital Professor of Medicine Harvard Medical School
PEPTIC ULCER DISEASE JOHN R SALTZMAN, MD Director of Endoscopy Brigham and Women s Hospital Professor of Medicine Harvard Medical School No disclosures Disclosures Overview Causes of peptic ulcer disease
More informationAcid-Peptic Diseases of the Stomach and Duodenum Including Helicobacter pylori and NSAIDs Prof. Sheila Crowe
Acid-Peptic Diseases of the Stomach and Duodenum Including Helicobacter pylori and NSAIDs 1 Division of Gastroenterology UC San Diego School of Medicine Clinical presentations of Helicobacter pylori infection
More informationEpidemiology of Peptic Ulcer Disease
Epidemiology of Peptic Ulcer Disease Introduction Peptic Ulcer Disease (PUD) is disruption of the mucosal integrity of the stomach and/or duodenum leading to a local defect or excavation due to active
More informationRisk Factors for the Presence of Symptoms in Peptic Ulcer Disease
ORIGINAL ARTICLE Clin Endosc 2017;50:578-584 https://doi.org/10.5946/ce.2016.129 Print ISSN 2234-2400 / On-line ISSN 2234-2443 Open Access Risk Factors for the Presence of Symptoms in Peptic Ulcer Disease
More informationINTRODUCTION ORIGINAL ARTICLE. Sang Gyun Kim 1, Nayoung Kim 2, Sung Kwan Shin 3, In Kyung Sung 4, Su Jin Hong 5 and Hyo-Jin Park 3
ORIGINAL ARTICLE Clin Endosc 2017;50:179-184 https://doi.org/10.5946/ce.2016.031 Print ISSN 2234-2400 On-line ISSN 2234-2443 Open Access Efficacy of Albis for the Prevention of Gastric Mucosal Injury Concomitant
More informationThe Risk Factors and Quality of Life in Patients with Overlapping Functional Dyspepsia or Peptic Ulcer Disease with Gastroesophageal Reflux Disease
Gut and Liver, Vol. 8, No. 2, March 2014, pp. 160-164 ORiginal Article The Risk Factors and Quality of Life in Patients with Overlapping Functional Dyspepsia or Peptic Ulcer Disease with Gastroesophageal
More informationPerspectives from Viet Nam
International Symposium I (Management of antibiotics-resistant Helicobacter pylori infection) Perspectives from Viet Nam Vu Van Khien 1,HoDangQuyDung 2, Tran Thanh Binh 2 1 Department of GI Endoscopy,
More informationHealth-related anxiety and the effect of open-access endoscopy in US patients with dyspepsia
Aliment Pharmacol Ther 23; 17: 835 84. doi: 1.146/j.269-2813.23.1497.x Health-related anxiety and the effect of open-access endoscopy in US patients with dyspepsia A. QUADRI & N. VAKIL University of Wisconsin
More informationThe effect of proton pump inhibitors on the gastric mucosal microenvironment
Original papers The effect of proton pump inhibitors on the gastric mucosal microenvironment Yen-Chun Peng,,, A F, Lan-Ru Huang, A, C, E, Hui-Ching Ho, C, Chi-Sen Chang, C, E, Shou-Wu Lee, E, Ching-Chang
More informationPrompt Upper Endoscopy Is an Appropriate Initial Management in Uninvestigated Chinese Patients With Typical Reflux Symptoms
nature publishing group ORIGINAL CONTRIBUTIONS 1947 Prompt Upper Endoscopy Is an Appropriate Initial Management in Uninvestigated Chinese Patients With Typical Reflux Symptoms Sui Peng, MD 1, Li-Shou Xiong,
More informationRapid increase in the prevalence of metronidazole resistant Helicobacter pylori in the Netherlands.
Chapter 2 Rapid increase in the prevalence of metronidazole resistant Helicobacter pylori in the Netherlands. E.J.van der Wouden 1, A.A.van Zwet 2, J.C.Thijs 1, G.D.C.Vosmaer 3, J.A.J.Oom 4, A.de Jong
More informationThe Nobel Prize in Physiology or Medicine for 2005
The Nobel Prize in Physiology or Medicine for 2005 jointly to Barry J. Marshall and J. Robin Warren for their discovery of "the bacterium Helicobacter pylori and its role in gastritis and peptic ulcer
More informationComparative study of invasive methods for diagnosis of Helicobacter pylori in humans
ISSN: 2319-7706 Volume 2 Number 7 (2013) pp. 63-68 http://www.ijcmas.com Original Research Article Comparative study of invasive methods for diagnosis of Helicobacter pylori in humans V.Subbukesavaraja
More informationProton Pump Inhibitor Treatment Decreases the Incidence of Upper Gastrointestinal Disorders in Elderly Japanese Patients Treated with NSAIDs
ORIGINAL ARTICLE Proton Pump Inhibitor Treatment Decreases the Incidence of Upper Gastrointestinal Disorders in Elderly Japanese Patients Treated with NSAIDs Yuki Sakamoto, Tadashi Shimoyama, Satoru Nakagawa,
More informationTreatment of Helicobacter pylori in Patients With Duodenal Ulcer Hemorrhage A Long-Term Randomized, Controlled Study
THE AMERICAN JOURNAL OF GASTROENTEROLOGY Vol. 95, No. 9, 2000 2000 by Am. Coll. of Gastroenterology ISSN 0002-9270/00/$20.00 Published by Elsevier Science Inc. PII S0002-9270(00)01041-8 Treatment of Helicobacter
More informationSetting The setting was primary care. The economic study was conducted in Canada.
Treating Helicobacter pylori infection in primary care patients with uninvestigated dyspepsia: the Canadian adult dyspepsia empiric treatment - Helicobacter pylori positive (CADET-Hp) randomised controlled
More informationStudy population The study population comprised hypothetical patients with gastric and duodenal ulcer.
Evaluation of the cost-effectiveness of Helicobacter pylori eradication triple therapy vs. conventional therapy for ulcers in Japan Ikeda S, Tamamuro T, Hamashima C, Asaka M Record Status This is a critical
More informationTRANSPARENCY COMMITTEE OPINION. 13 December 2006
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 13 December 2006 HELIKIT 75 mg, powder for oral solution CIP : 343 132-1 Applicant : MAYOLY SPINDLER 13 Curea anhydrous
More informationIbuprofen versus other non-steroidal anti-in ammatory drugs: use in general practice and patient perception
Aliment Pharmacol Ther 2000; 14: 187±191. Ibuprofen versus other non-steroidal anti-in ammatory drugs: use in general practice and patient perception C. J. HAWKEY 1,D.J.E.CULLEN 1,9,G.PEARSON 1,S.HOLMES
More information6/25/ % 20% 50% 19% Functional Dyspepsia Peptic Ulcer GERD Cancer Other
Peptic Ulcer Disease and Dyspepsia John M. Inadomi, MD Professor of Medicine UCSF Chief, Clinical Gastroenterology San Francisco General Hospital Case History 49 y/o woman complains of several months of
More informationMANAGEMENT OF DYSPEPSIA AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT OF DYSPEPSIA AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) Routine endoscopic investigation of patients of any age, presenting with dyspepsia
More informationUpper Gastrointestinal Complications and Cardiovascular/ Gastrointestinal Risk Calculator in Patients with Myocardial Infarction Treated with Aspirin
Original Article Upper Gastrointestinal Complications and Cardiovascular/ Gastrointestinal Risk Calculator in Patients with Myocardial Infarction Treated with Aspirin Lei Wen Department of Gastroenterology,
More informationOriginal Article. Abstract. Introduction
Original Article Frequency of NSAID Induced Peptic Ulcer Disease Saeed Hamid, Javed Yakoob, Wasim Jafri, Shanul Islam, Shahab Abid, Muhammad Islam Section of Gastroenterology, Department of Medicine, Aga
More informationGASTROINTESTINAL AND ANTIEMETIC DRUGS. Submitted by: Shaema M. Ali
GASTROINTESTINAL AND ANTIEMETIC DRUGS Submitted by: Shaema M. Ali GASTROINTESTINAL AND ANTIEMETIC DRUGS by: Shaema M. Ali There are four common medical conditions involving the GI system 1) peptic ulcers
More informationA Heaney, J S A Collins, RGPWatson, R J McFarland, K B Bamford, T C K Tham
186 Royal Victoria Hospital, Belfast, A Heaney J S A Collins Department of Medicine, Queen s University, Belfast, RGPWatson Ulster Hospital, Dundonald, R J McFarland T C K Tham Department of Microbiology
More informationNon-Ulcer Dyspepsia: what is it? What can we do with these patients? Overview. Dyspepsia Definition. Functional Dyspepsia. Dyspepsia the Basics
Non-Ulcer : what is it? What can we do with these patients? Temporal Changes and Geographic Variations in Developing Peptic Ulcer Disease Gastric Cancer 1900 Eamonn M M Quigley MD FACG Alimentary Pharmabiotic
More informationWorld Journal Of Gastroenterology, 2005, v. 11 n. 23, p
Title Patients with Helicobacter pylori positive and negative duodenal ulcers have distinct clinical characteristics Author(s) Chu, KM; Kwok, KF; Law, S; Wong, KH Citation World Journal Of Gastroenterology,
More informationLow Dose Furazolidone for Eradication of H- pylori Instead of Clarithromycin: A Clinical Trial
Global Journal of Health Science; Vol. 7, No. 1; 2015 ISSN 1916-9736 E-ISSN 1916-9744 Published by Canadian Center of Science and Education Low Dose Furazolidone for Eradication of H- pylori Instead of
More informationH elicobacter pylori is a human pathogen that causes
1543 STOMACH Effect of Helicobacter pylori eradication on development of dyspeptic and reflux disease in healthy asymptomatic subjects D Vaira, N Vakil, M Rugge, L Gatta, C Ricci, M Menegatti, G Leandro,
More informationPEER REVIEW HISTORY ARTICLE DETAILS
PEER REVIEW HISTORY BMJ Open publishes all reviews undertaken for accepted manuscripts. Reviewers are asked to complete a checklist review form (http://bmjopen.bmj.com/site/about/resources/checklist.pdf)
More informationSetting The setting was primary care. The economic analysis was conducted in Glasgow, UK.
Helicobacter pylori eradication for peptic ulceration: an observational study in a Scottish primary care setting Forrest E H, MacKenzie J F, Stuart R C, Morris A J Record Status This is a critical abstract
More informationPatterns of alcohol consumption and Helicobacter pylori infection: results of a population-based study from Germany among 6545 adults
Aliment Pharmacol Ther 2005; 21: 57 64. doi: 10.1111/j.1365-2036.2004.02276.x Patterns of alcohol consumption and Helicobacter pylori infection: results of a population-based study from Germany among 6545
More informationOne-third of adults experience pain or discomfort in
GASTROENTEROLOGY 2002;122:1270 1285 Dyspepsia Management in Primary Care: A Decision Analysis of Competing Strategies BRENNAN M. R. SPIEGEL,* NIMISH B. VAKIL, and JOSHUA J. OFMAN*, *Department of Medicine
More informationOne-week low-dose triple therapy for Helicobacter pylori is sufficient for relief from symptoms and healing of duodenal ulcers
Aliment Pharmacol Ther 1997; 11: 89 93. One-week low-dose triple therapy for Helicobacter pylori is sufficient for relief from symptoms and healing of duodenal ulcers J. LABENZ*, J.-P. IDSTRO M, B. TILLENBURG*,
More informationRole of Helicobacter pylori in ulcer healing and
22 Departments of Gastroenterology G Bianchi Porro F Parente V Imbesi and Rheumatology F Montrone I Caruso L Sacco University Hospital, Milan, Italy Correspondence to: Professor G Bianchi Porro, Gastrointestinal
More informationHelicobacter pylori Eradication within 120 Days Is Associated with Decreased Complicated Recurrent Peptic Ulcers in Peptic Ulcer Bleeding Patients
Gut and Liver, Vol. 9, No. 3, May 2015, pp. 346-352 ORiginal Article Helicobacter pylori Eradication within 120 Days Is Associated with Decreased Complicated Recurrent Peptic Ulcers in Peptic Ulcer Bleeding
More informationEffect of Helicobacter pylori infection and its eradication on nutrition
Aliment Pharmacol Ther 2002; 16: 799 806. Effect of Helicobacter pylori infection and its eradication on nutrition T. FURUTA*, N. SHIRAI*, F. XIAO*, M. TAKASHIMA* & H. HANAI *First Department of Medicine
More informationKK College of Nursing Peptic Ulcer Badil D ass Dass, Lecturer 25th July, 2011
KK College of Nursing Peptic Ulcer Badil Dass, Lecturer 25 th July, 2011 Objectives: By the end of this lecture, the students t will be able to: Define peptic pp ulcer Describe the etiology and pathology
More informationThe long-term management of patients with bleeding duodenal ulcers
Aliment Pharmacol Ther (1997); 11: 505±510. The long-term management of patients with bleeding duodenal ulcers M. E. MCALINDON, J. S. W. TAYLOR & S. D. RYDER Department of Medicine, University Hospital,
More informationHave COX-2 inhibitors influenced the co-prescription of anti-ulcer drugs with NSAIDs?
et al. DOI:10.1111/j.1365-2125.2003.02012.x British Journal of Clinical Pharmacology Have COX-2 inhibitors influenced the co-prescription of anti-ulcer drugs with NSAIDs? Mary Teeling, Kathleen Bennett
More informationH. pylori Antigen ELISA Kit
H. pylori Antigen ELISA Kit Catalog Number KA3142 96 assays Version: 04 Intended for research use only www.abnova.com Table of Contents Introduction... 3 Intended Use... 3 Background... 3 Principle of
More informationHelicobacter pyloni and upper gastrointestinal
314 Helicobacter pyloni and upper gastrointestinal disease: a survey of gastroenterologists in the United Kingdom Gut 1995; 37: 314-318 R Milne, R P H Logan, D Harwood, J J Misiewicz, D Forman Health Services
More informationA PLACEBO CONTROLLED TRIAL OF BISMUTH SALICYLATE IN HELICOBACTER PYLORI ASSOCIATED GASTRITIS
A PLACEBO CONTROLLED TRIAL OF BISMUTH SALICYLATE IN HELICOBACTER PYLORI ASSOCIATED GASTRITIS Pages with reference to book, From 154 To 156 Javed Iqbal Kazi, Naeem Aon Jafarey, Syed Mahmood Alam ( Department
More informationH. Pylori and Dyspepsia
Focus on CME at the University of Queen s ManitobaUniversity H. Pylori and Dyspepsia By Japie Louw, MB, ChB, FCP(SA), FRCPC, Med PhD Since its rediscovery in the early 1980 s, Helicobacter pylori (H. Pylori)
More informationPrevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin
Aliment Pharmacol Ther 2005; 22: 795 801. doi: 10.1111/j.1365-2036.2005.02649.x Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin N. D. YEOMANS*,
More informationHelicobacter pylori infection: several studies on epidemiology, eradication and gastric epithelial cell turnover Liu, W.
UvA-DARE (Digital Academic Repository) Helicobacter pylori infection: several studies on epidemiology, eradication and gastric epithelial cell turnover Liu, W. Link to publication Citation for published
More informationEDUCATION PRACTICE. Persistent Helicobacter pylori Infection After a Course of Antimicrobial Therapy What s Next? Clinical Scenario.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2008;6:1086 1090 EDUCATION PRACTICE Persistent Helicobacter pylori Infection After a Course of Antimicrobial Therapy What s Next? RICHARD J. SAAD* and WILLIAM D.
More informationPeptic Ulcer Disease Today
1 of 11 2/24/2007 2:54 PM www.medscape.com To Print: Click your browser's PRINT button. NOTE: To view the article with Web enhancements, go to: http://www.medscape.com/viewarticle/522900 Peptic Ulcer Disease
More informationTECHNOLOGY OVERVIEW: PHARMACEUTICALS
TECHNOLOGY OVERVIEW: PHARMACEUTICALS ISSUE 3.1 JUNE 1996 PHARMACEUTICAL MANAGEMENT OF PEPTIC ULCER DISEASE prepared by Ms. Christine Perras, BSc Phm Pharmaceutical Associate, CCOHTA and Dr. Nicolaas Otten,
More informationHelicobacter Connections. Barry Marshall
Helicobacter Connections Barry Marshall The greatest obstacle to knowledge is not ignorance, it is the illusion of knowledge. Daniel Boorstein - Historian Peptic Ulcers Duodenal Ulcer (DU) Gastric Ulcer
More informationDERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT OF DYSPEPSIA
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT OF DYSPEPSIA o Patients of any age with ALARM signs should be referred through the 2-week referral system o Routine endoscopic investigation
More informationDisclosures. Co-founder and Chief Science Officer, TechLab
H. pylori testing Disclosures Co-founder and Chief Science Officer, TechLab Learning Objectives Evaluate the appropriate testing methodology by balancing performance, economics, and workflow. Discuss the
More informationA Study of the Correlation between Endoscopic and Histological Diagnoses in Gastroduodenitis
000-9 70/8 7/80S-0749 THE AMERICAN JOIIRNAE. OF GAsrR()E.NrER 1987 by Am. Coll.ofGastroenterology Vo!.8. No. 8, 1487 Printed in U.S.A. A Study of the Correlation between Endoscopic
More information